Related Experiment Video
Updated: Jul 8, 2025
11:30
A Semi-Automated and Reproducible Biological-Based Method to Quantify Calcium Deposition In Vitro
Published on: June 2, 2022
2.0K
Osteoporosis in Renal Disease.
1Department of Nephrology, Goa Medical College, Bambolim, Goa 403202 India.
Indian Journal of Orthopaedics
|December 18, 2023
Summary
Osteoporosis, a condition of reduced bone mass and increased fracture risk, is common in chronic kidney disease (CKD). Management strategies for osteoporosis in CKD patients vary by disease stage, emphasizing fracture prevention.
Area of Science:
- Nephrology
- Endocrinology
- Bone Metabolism
Background:
- Osteoporosis is characterized by decreased bone mass and increased fracture risk.
- Chronic kidney disease (CKD) is associated with diverse bone metabolic disorders, including osteoporosis.
- Osteoporosis is prevalent in early CKD stages and coexists with renal osteodystrophy in later stages.
Purpose of the Study:
- To summarize the relationship between osteoporosis and chronic kidney disease.
- To outline the risk factors, diagnostic criteria, and management principles for osteoporosis in CKD patients.
Main Methods:
- Review of literature on osteoporosis and CKD.
- Analysis of diagnostic approaches including bone mineral density (BMD) assessment and exclusion of CKD-mineral bone disorder (CKD-MBD).
- Examination of treatment variations based on CKD stages.
Main Results:
- Osteoporosis prevalence is significant in CKD patients.
- Diagnosis requires BMD assessment, CKD-MBD exclusion, fracture history, and laboratory tests.
- Treatment for osteoporosis in early CKD stages (1-3) aligns with general population guidelines, with a focus on fracture prevention.
Conclusions:
- Osteoporosis is a significant concern in patients with chronic kidney disease.
- A comprehensive diagnostic approach is crucial for accurate osteoporosis diagnosis in CKD.
- Tailored management strategies, prioritizing fracture prevention, are essential for osteoporosis in CKD.
Related Concept Videos
01:29Bone Disorders
3.5K
Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
3.5K
01:11Renal Failure: Dose Adjustments
95
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
95
01:40Bone Remodeling
38.3K
Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.
38.3K
01:31Osteoclasts in Bone Remodeling
3.0K
Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during...
3.0K
01:29Renal Regulation of Acid-Base Balance
460
Metabolic reactions in the body produce nonvolatile acids, such as sulfuric acid, which generate an acid load of approximately 1 mEq of H+ per kilogram of body weight daily. Excreting H+ in the urine is essential to balance this acid load.
In the kidneys, cells within the proximal convoluted tubules (PCT) and the collecting ducts secrete hydrogen ions (H+) into the tubular fluid. Specifically, in the PCT, Na+/H+ antiporters secrete H+ while reabsorbing Na+.
However, the intercalated cells in...
In the kidneys, cells within the proximal convoluted tubules (PCT) and the collecting ducts secrete hydrogen ions (H+) into the tubular fluid. Specifically, in the PCT, Na+/H+ antiporters secrete H+ while reabsorbing Na+.
However, the intercalated cells in...
460
01:28Renal Drug Excretion: Tubular Secretion
192
Active tubular secretion is a robust, energy-demanding process that utilizes carrier systems to transport drugs into renal tubules. The active renal secretion systems include the organic anion transporter (OAT) for weak acids and the organic cation transporter (OCT) for weak bases. Structurally similar drugs can compete for the same transporter, potentially leading to drug accumulation and toxicity. However, this principle can be exploited therapeutically. One example is probenecid (Probalan),...
192